How the TP53 Family Proteins TP63 and TP73 contribute to tumorigenesis: Regulators and effectors

Human Mutation

Volumn 35, Issue 6, 2014, Pages 702-714

  Candi, Eleonora ^a   Agostini, Massimiliano ^b   Melino, Gerry ^a,b   Bernassola, Francesca ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Cellular metabolism; MicroRNA; P53; P63; P73; TP53; TP63; TP73; Ubiquitylation

Indexed keywords

MICRORNA; PROTEIN P53; PROTEIN P63; PROTEIN P73; UBIQUITIN PROTEIN LIGASE E3; DNA BINDING PROTEIN; NUCLEAR PROTEIN; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

BINDING SITE; CARCINOGENESIS; CELL METABOLISM; DETOXIFICATION; DOWN REGULATION; ENERGY METABOLISM; GENE CONTROL; HUMAN; IMMUNE RESPONSE; LIPID METABOLISM; MOLECULAR INTERACTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; TRANSCRIPTION INITIATION; UPREGULATION; ANIMAL; GENETICS; PROMOTER REGION; UBIQUITINATION;

MAMMALIA;

ANIMALS; CARCINOGENESIS; DNA-BINDING PROTEINS; HUMANS; MICRORNAS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UBIQUITINATION;

EID: 84901244771     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22523     Document Type: Review

References (156)

1. Aberdam D, Candi E, Knight RA, Melino G. 2008. miRNAs, 'stemness' and skin. Trends Biochem Sci 33:583-591.
2. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, Parenti AR, Rosato A, et al. 2009. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137:87-98.
3. Agami R, Blandino G, Oren M, Shaul Y. 1999. Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature 399:809-813.
4. Agostini M, Tucci P, Chen H, Knight RA, Bano D, Nicotera P, McKeon F, Melino G. 2010. p73 regulates maintenance of neural stem cell. Biochem Biophys Res Commun 403:13-17.
5. Agostini M, Tucci P, Killick R, Candi E, Sayan BS, Rivetti di Val Cervo P, Nicotera P, McKeon F, Knight RA, Mak TW, Melino G. 2011a. Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc Natl Acad Sci USA 108:21093-21098.
6. Agostini M, Tucci P, Steinert JR, Shalom-Feuerstein R, Rouleau M, Aberdam D, Forsythe ID, Young KW, Ventura A, Concepcion CP, Han YC, Candi E, et al. 2011b. microRNA-34a regulates neurite outgrowth, spinal morphology, and function. Proc Natl Acad Sci USA 108:21099-21104.
7. Al-Bahlani S, Fraser M, Wong AY, Sayan BS, Bergeron R, Melino G, Tsang BK. 2011. P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism. Oncogene 30:4219-4230.
8. Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M, Putzer BM. 2012. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 11:3067-3078.
9. Amelio I, Markert EK, Rufini A, Antonov AV, Sayan BS, Tucci P, Agostini M, Mineo TC, Levine AJ, Melino G. 2013. p73 regulates serine biosynthesis in cancer. Oncogene. [Epub ahead of print.]
10. Antonini D, Russo MT, De Rosa L, Gorrese M, Del Vecchio L, Missero C. 2010. Transcriptional repression of miR-34 family contributes to p63-mediated cell cycle progression in epidermal cells. J Invest Dermatol 130:1249-1257.
11. Asher G, Tsvetkov P, Kahana C, Shaul Y. 2005. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev 19:316-321.
12. Bernassola F, Oberst A, Melino G, Pandolfi PP. 2005. The promyelocytic leukaemia protein tumour suppressor functions as a transcriptional regulator of p63. Oncogene 24:6982-6986.
13. Bernassola F, Salomoni P, Oberst A, Di Como CJ, Pagano M, Melino G, Pandolfi PP. 2004. Ubiquitin-dependent degradation of p73 is inhibited by PML. J Exp Med 199:1545-1557.
14. Billon N, Terrinoni A, Jolicoeur C, McCarthy A, Richardson WD, Melino G, Raff M. 2004. Roles for p53 and p73 during oligodendrocyte development. Development 131:1211-1220.
15. Cairns RA, Harris IS, Mak TW. 2011. Regulation of cancer cell metabolism. Nat Rev Cancer 11:85-95.
16. Calabro V, Mansueto G, Parisi T, Vivo M, Calogero RA, La Mantia G. 2002. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J Biol Chem 277:2674-2681.
17. Candi E, Dinsdale D, Rufini A, Salomoni P, Knight RA, Mueller M, Krammer PH, Melino G. 2007a. TAp63 and DeltaNp63 in cancer and epidermal development. Cell Cycle 6:274-285.
18. Candi E, Rufini A, Terrinoni A, Giamboi-Miraglia A, Lena AM, Mantovani R, Knight R, Melino G. 2007b. DeltaNp63 regulates thymic development through enhanced expression of FgfR2 and Jag2. Proc Natl Acad Sci USA 104:11999-2004.
19. Chae YS, Kim H, Kim D, Lee H, Lee HO. 2012. Cell density-dependent acetylation of DeltaNp63alpha is associated with p53-dependent cell cycle arrest. FEBS Lett 586:1128-1134.
20. Chikh A, Matin RN, Senatore V, Hufbauer M, Lavery D, Raimondi C, Ostano P, Mello-Grand M, Ghimenti C, Bahta A, Khalaf S, Akgül B, et al. 2011. iASPP/p63 autoregulatory feedback loop is required for the homeostasis of stratified epithelia. EMBO J 30:4261-4273.
21. Conforti F, Sayan AE, Sreekumar R, Sayan BS. 2012. Regulation of p73 activity by post-translational modifications. Cell Death Dis 3:e285.
22. Cook CC, Kim A, Terao S, Gotoh A, Higuchi M. 2012. Consumption of oxygen: a mitochondrial-generated progression signal of advanced cancer. Cell Death Dis 3:e258.
23. Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, Fontemaggi G, Fanciulli M, Schiltz L, Blandino G, Balsano C, Levrero M. 2002. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell 9:175-186.
24. Crighton D, O'Prey J, Bell HS, Ryan KM. 2007. p73 regulates DRAM-independent autophagy that does not contribute to programmed cell death. Cell Death Differ 14:1071-1079.
25. De Laurenzi V, Raschella G, Barcaroli D, Annicchiarico-Petruzzelli M, Ranalli M, Catani MV, Tanno B, Costanzo A, Levrero M, Melino G. 2000. Induction of neuronal differentiation by p73 in a neuroblastoma cell line. J Biol Chem 275:15226-15231.
26. Denton D, Nicolson S, Kumar S. 2012. Cell death by autophagy: facts and apparent artefacts. Cell Death Differ 19:87-95.
27. Deutsch GB, Zielonka EM, Coutandin D, Weber TA, Schafer B, Hannewald J, Luh LM, Durst FG, Ibrahim M, Hoffmann J, Niesen FH, Sentürk A, et al. 2011. DNA damage in oocytes induces a switch of the quality control factor TAp63alpha from dimer to tetramer. Cell 144:566-576.
28. Dotsch V, Bernassola F, Coutandin D, Candi E, Melino G. 2010. p63 and p73, the ancestors of p53. Cold Spring Harb Perspect Biol 2:a004887.
29. Du W, Jiang P, Mancuso A, Stonestrom A, Brewer MD, Minn AJ, Mak TW, Wu M, Yang X. 2013. TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat Cell Biol 15:991-1000.
30. Dulloo I, Gopalan G, Melino G, Sabapathy K. 2010. The antiapoptotic DeltaNp73 is degraded in a c-Jun-dependent manner upon genotoxic stress through the antizyme-mediated pathway. Proc Natl Acad Sci USA 107:4902-4907.
31. Ethayathulla AS, Tse PW, Monti P, Nguyen S, Inga A, Fronza G, Viadiu H. 2012. Structure of p73 DNA-binding domain tetramer modulates p73 transactivation. Proc Natl Acad Sci USA 109:6066-6071.
32. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, et al. 2007. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 104:15805-15810.
33. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D, Yang A, McKeon F, Jacks T. 2005. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7:363-373.
34. Gallegos JR, Litersky J, Lee H, Sun Y, Nakayama K, Nakayama K, Lu H. 2008. SCF TrCP1 activates and ubiquitylates TAp63gamma. J Biol Chem 283:66-75.
35. Galli F, Rossi M, D'Alessandra Y, De Simone M, Lopardo T, Haupt Y, Alsheich-Bartok O, Anzi S, Shaulian E, Calabro V, La Mantia G, Guerrini L. 2010. MDM2 and Fbw7 cooperate to induce p63 protein degradation following DNA damage and cell differentiation. J Cell Sci 123:2423-2433.
36. Gandellini P, Profumo V, Casamichele A, Fenderico N, Borrelli S, Petrovich G, Santilli G, Callari M, Colecchia M, Pozzi S, De Cesare M, Folini M, et al. 2010. miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death Differ. 19:1750-1760.
37. Ghioni P, Bolognese F, Duijf PH, Van Bokhoven H, Mantovani R, Guerrini L. 2002. Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol Cell Biol 22:8659-8668.
38. Ghioni P, D'Alessandra Y, Mansueto G, Jaffray E, Hay RT, La Mantia G, Guerrini L. 2005. The protein stability and transcriptional activity of p63alpha are regulated by SUMO-1 conjugation. Cell Cycle 4:183-190.
39. Giacobbe A, Bongiorno-Borbone L, Bernassola F, Terrinoni A, Markert EK, Levine AJ, Feng Z, Agostini M, Zolla L, Agrò AF, Notterman DA, Melino G, et al. 2013. p63 regulates glutaminase 2 expression. Cell Cycle 12:1395-1405.
40. Gonfloni S, Di Tella L, Caldarola S, Cannata SM, Klinger FG, Di Bartolomeo C, Mattei M, Candi E, De Felici M, Melino G, Cesareni G. 2009. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med 15:1179-1185.
41. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG Jr., Levrero M, Wang JY. 1999. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399:806-809.
42. Gonzalez-Cano L, Hillje AL, Fuertes-Alvarez S, Marques MM, Blanch A, Ian RW, Irwin MS, Schwamborn JC, Marin MC. 2013. Regulatory feedback loop between TP73 and TRIM32. Cell Death Dis 4:e704.
43. Graupner V, Alexander E, Overkamp T, Rothfuss O, De Laurenzi V, Gillissen BF, Daniel PT, Schulze-Osthoff K, Essmann F. 2011. Differential regulation of the proapoptotic multidomain protein Bak by p53 and p73 at the promoter level. Cell Death Differ 18:1130-1139.
44. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. 2008. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10:593-601.
45. Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W, Pandolfi PP. 2000. The function of PML in p53-dependent apoptosis. Nat Cell Biol 2:730-736.
46. Guo X, Keyes WM, Papazoglu C, Zuber J, Li W, Lowe SW, Vogel H, Mills AA. 2009. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol 11:1451-1457.
47. He Z, Liu H, Agostini M, Yousefi S, Perren A, Tschan MP, Mak TW, Melino G, Simon HU. 2013. p73 regulates autophagy and hepatocellular lipid metabolism through a transcriptional activation of the ATG5 gene. Cell Death Differ 20:1415-1424.
48. Hosoda M, Ozaki T, Miyazaki K, Hayashi S, Furuya K, Watanabe K, Nakagawa T, Hanamoto T, Todo S, Nakagawara A. 2005. UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination. Oncogene 24:7156-7169.
49. Huang Y, Kesselman D, Kizub D, Guerrero-Preston R, Ratovitski EA. 2013. Phospho-DeltaNp63alpha/microRNA feedback regulation in squamous carcinoma cells upon cisplatin exposure. Cell Cycle 12:684-697.
50. Huang YP, Wu G, Guo Z, Osada M, Fomenkov T, Park HL, Trink B, Sidransky D, Fomenkov A, Ratovitski EA. 2004. Altered sumoylation of p63alpha contributes to the split-hand/foot malformation phenotype. Cell Cycle 3:1587-1596.
51. Inoue S, Harper N, Walewska R, Dyer MJ, Cohen GM. 2009. Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis. Mol Cancer Ther 8:3088-3097.
52. Jordan JJ, Menendez D, Inga A, Noureddine M, Bell DA, Resnick MA. 2008. Noncanonical DNA motifs as transactivation targets by wild type and mutant p53. PLoS Genet 4:e1000104.
53. Kadakia M, Slader C, Berberich SJ. 2001. Regulation of p63 function by Mdm2 and MdmX. DNA Cell Biol 20:321-330.
54. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, et al. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819.
55. Kasinski AL, Slack FJ. 2011. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 11:849-864.
56. Kenzelmann Broz D, Spano Mello S, Bieging KT, Jiang D, Dusek RL, Brady CA, Sidow A, Attardi LD. 2013. Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses. Genes Dev 27:1016-1031.
57. Keyes WM, Vogel H, Koster MI, Guo X, Qi Y, Petherbridge KM, Roop DR, Bradley A, Mills AA. 2006. p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc Natl Acad Sci USA 103:8435-8440.
58. Killick R, Niklison-Chirou M, Tomasini R, Bano D, Rufini A, Grespi F, Velletri T, Tucci P, Sayan BS, Conforti F, Gallagher E, Nicotera P, et al. 2011. p73: a multifunctional protein in neurobiology. Mol Neurobiol 43:139-146.
59. Kim EJ, Park JS, Um SJ. 2002. Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo. J Biol Chem 277:32020-32028.
60. Kim EJ, Park JS, Um SJ. 2003. Identification of Daxx interacting with p73, one of the p53 family, and its regulation of p53 activity by competitive interaction with PML. Nucleic Acids Res 31:5356-5367.
61. Knouf EC, Garg K, Arroyo JD, Correa Y, Sarkar D, Parkin RK, Wurz K, O'Briant KC, Godwin AK, Urban ND, Ruzzo WL, Gentleman R, et al. 2012. An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription. Nucleic Acids Res 40:499-510.
62. Kondo Y, Kanzawa T, Sawaya R, Kondo S. 2005. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5:726-734.
63. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, et al. 2009. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 16:3-11.
64. Laine A, Ronai Z. 2007. Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1. Oncogene 26:1477-1483.
65. Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G, Pandolfi PP, Givol D, Strano S, Lu X, Blandino G. 2008. PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell 32:803-814.
66. Lazzari C, Prodosmo A, Siepi F, Rinaldo C, Galli F, Gentileschi M, Bartolazzi A, Costanzo A, Sacchi A, Guerrini L, Soddu S. 2011. HIPK2 phosphorylates DeltaNp63alpha and promotes its degradation in response to DNA damage. Oncogene 30:4802-4813.
67. Lena AM, Shalom-Feuerstein R, Rivetti di Val Cervo P, Aberdam D, Knight RA, Melino G, Candi E. 2008. miR-203 represses 'stemness' by repressing DeltaNp63. Cell Death Differ 15:1187-1195.
68. Levine B, Klionsky DJ. 2004. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6:463-477.
69. Levy D, Adamovich Y, Reuven N, Shaul Y. 2007. The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death Differ 14:743-751.
70. Levy D, Adamovich Y, Reuven N, Shaul Y. 2008a. Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol Cell 29:350-361.
71. Levy D, Reuven N, Shaul Y. 2008b. A regulatory circuit controlling Itch-mediated p73 degradation by Runx. J Biol Chem 283:27462-27468.
72. Li Y, Peart MJ, Prives C. 2009. Stxbp4 regulates DeltaNp63 stability by suppression of RACK1-dependent degradation. Mol Cell Biol 29:3953-39563.
73. Li Y, Zhou Z, Chen C. 2008. WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death Differ 15:1941-1951.
74. Liao JM, Zhang Y, Liao W, Zeng SX, Su X, Flores ER, Lu H. 2013. IkappaB kinase beta (IKKbeta) inhibits p63 isoform gamma (TAp63gamma) transcriptional activity. J Biol Chem 288:18184-18193.
75. Luh LM, Kehrloesser S, Deutsch GB, Gebel J, Coutandin D, Schafer B, Agostini M, Melino G, Dotsch V. 2013. Analysis of the oligomeric state and transactivation potential of TAp73alpha. Cell Death Differ 20:1008-1016.
76. MacPartlin M, Zeng S, Lee H, Stauffer D, Jin Y, Thayer M, Lu H. 2005. p300 regulates p63 transcriptional activity. J Biol Chem 280:30604-30610.
77. Maddocks OD, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E, Vousden KH. 2013. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 493:542-546.
78. Maiuri MC, Tasdemir E, Criollo A, Morselli E, Vicencio JM, Carnuccio R, Kroemer G. 2009. Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ 16:87-93.
79. Manca S, Magrelli A, Cialfi S, Lefort K, Ambra R, Alimandi M, Biolcati G, Uccelletti D, Palleschi C, Screpanti I, Candi E, Melino G. 2011. Oxidative stress activation of miR-125b is part of the molecular switch for Hailey-Hailey disease manifestation. Exp Dermatol 20:932-937.
80. Mangiulli M, Valletti A, Caratozzolo MF, Tullo A, Sbisa E, Pesole G, D'Erchia AM. 2009. Identification and functional characterization of two new transcriptional variants of the human p63 gene. Nucleic Acids Res 37:6092-6104.
81. Manni I, Artuso S, Careccia S, Rizzo MG, Baserga R, Piaggio G, Sacchi A. 2009. The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEB J 23:3957-3966.
82. Mantovani F, Piazza S, Gostissa M, Strano S, Zacchi P, Mantovani R, Blandino G, Del Sal G. 2004. Pin1 links the activities of c-Abl and p300 in regulating p73 function. Mol Cell 14:625-636.
83. Marcel V, Petit I, Murray-Zmijewski F, Goullet de Rugy T, Fernandes K, Meuray V, Diot A, Lane DP, Aberdam D, Bourdon JC. 2012. Diverse p63 and p73 isoforms regulate Delta133p53 expression through modulation of the internal TP53 promoter activity. Cell Death Differ 19:816-826.
84. Masse I, Barbollat-Boutrand L, Molina M, Berthier-Vergnes O, Joly-Tonetti N, Martin MT, Caron de Fromentel C, Kanitakis J, Lamartine J. 2012. Functional interplay between p63 and p53 controls RUNX1 function in the transition from proliferation to differentiation in human keratinocytes. Cell Death Dis 3:e318.
85. Matin RN, Chikh A, Chong SL, Mesher D, Graf M, Sanza P, Senatore V, Scatolini M, Moretti F, Leigh IM, Proby CM, Costanzo A, et al. 2013. p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J Exp Med 210:581-603.
86. Melino G. 2011. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ 18:1487-1499.
87. Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, Corazzari M, Knight RA, Green DR, Thompson C, Vousden KH. 2004. p73 induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 279:8076-8083.
88. Melino G, De Laurenzi V, Vousden KH. 2002. p73: friend or foe in tumorigenesis. Nat Rev Cancer 2:605-615.
89. Melino G, Gallagher E, Aqeilan RI, Knight R, Peschiaroli A, Rossi M, Scialpi F, Malatesta M, Zocchi L, Browne G, Ciechanover A, Bernassola F. 2008. Itch: a HECT-type E3 ligase regulating immunity, skin and cancer. Cell Death Differ 15:1103-1112.
90. Melino G, Knight RA, Nicotera P. 2005. How many ways to die? How many different models of cell death? Cell Death Differ 12 (Suppl 2):1457-1462.
91. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. 1999. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398:708-713.
92. Mizushima N, Levine B. 2010. Autophagy in mammalian development and differentiation. Nat Cell Biol 12:823-830.
93. Munarriz E, Bano D, Sayan AE, Rossi M, Melino G, Nicotera P. 2005. Calpain cleavage regulates the protein stability of p73. Biochem Biophys Res Commun 333:954-960.
94. Munarriz E, Barcaroli D, Stephanou A, Townsend PA, Maisse C, Terrinoni A, Neale MH, Martin SJ, Latchman DS, Knight RA, Melino G, De Laurenzi V. 2004. PIAS-1 is a checkpoint regulator which affects exit from G1 and G2 by sumoylation of p73. Mol Cell Biol 24:10593-10610.
95. Munoz-Pinedo C, El Mjiyad N, Ricci JE. 2012. Cancer metabolism: current perspectives and future directions. Cell Death Dis 3:e248.
96. Murray-Zmijewski F, Lane DP, Bourdon JC. 2006. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 13:962-972.
97. Niklison-Chirou MV, Steinert JR, Agostini M, Knight RA, Dinsdale D, Cattaneo A, Mak TW, Melino G. 2013. TAp73 knockout mice show morphological and functional nervous system defects associated with loss of p75 neurotrophin receptor. Proc Natl Acad Sci USA 110:18952-18957.
98. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. 2010. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140:49-61.
99. Oberst A, Malatesta M, Aqeilan RI, Rossi M, Salomoni P, Murillas R, Sharma P, Kuehn MR, Oren M, Croce CM, Bernassola F, Melino G. 2007. The Nedd4-binding partner 1 (N4BP1) protein is an inhibitor of the E3 ligase Itch. Proc Natl Acad Sci USA 104:11280-11285.
100. Ohtsuka T, Ryu H, Minamishima YA, Ryo A, Lee SW. 2003. Modulation of p53 and p73 levels by cyclin G: implication of a negative feedback regulation. Oncogene 22:1678-1687.
101. Ongkeko WM, Wang XQ, Siu WY, Lau AW, Yamashita K, Harris AL, Cox LS, Poon RY. 1999. MDM2 and MDMX bind and stabilize the p53-related protein p73. Curr Biol 9:829-832.
102. Ory B, Ramsey MR, Wilson C, Vadysirisack DD, Forster N, Rocco JW, Rothenberg SM, Ellisen LW. 2011. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest 121:809-820.
103. Ou HD, Lohr F, Vogel V, Mantele W, Dotsch V. 2007. Structural evolution of C-terminal domains in the p53 family. EMBO J 26:3463-3473.
104. Papagiannakopoulos T, Shapiro A, Kosik KS. 2008. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 68:8164-8172.
105. Paris M, Rouleau M, Puceat M, Aberdam D. 2012. Regulation of skin aging and heart development by TAp63. Cell Death Differ 19:186-193.
106. Peschiaroli A, Scialpi F, Bernassola F, El Sherbini el S, Melino G. 2010. The E3 ubiquitin ligase WWP1 regulates DeltaNp63-dependent transcription through Lys63 linkages. Biochem Biophys Res Commun 402:425-430.
107. Peschiaroli A, Scialpi F, Bernassola F, Pagano M, Melino G. 2009. The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73. Oncogene 28:3157-3166.
108. Pignon JC, Grisanzio C, Geng Y, Song J, Shivdasani RA, Signoretti S. 2013. p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. Proc Natl Acad Sci USA 110:8105-8110.
109. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD. 2000. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289:304-306.
110. Puca R, Nardinocchi L, Sacchi A, Rechavi G, Givol D, D'Orazi G. 2009. HIPK2 modulates p53 activity towards pro-apoptotic transcription. Mol Cancer 8:85.
111. Ratovitski EA, Patturajan M, Hibi K, Trink B, Yamaguchi K, Sidransky D. 2001. p53 associates with and targets Delta Np63 into a protein degradation pathway. Proc Natl Acad Sci USA 98:1817-1822.
112. Rivetti di Val Cervo P, Lena AM, Nicoloso M, Rossi S, Mancini M, Zhou H, Saintigny G, Dellambra E, Odorisio T, Mahe C, Calin GA, Candi E, et al. 2012. p63-microRNA feedback in keratinocyte senescence. Proc Natl Acad Sci USA 109:1133-1138.
113. Rivetti di Val Cervo P, Tucci P, Majid A, Lena AM, Agostini M, Bernardini S, Candi E, Cohen G, Nicotera P, Dyer MJ, Melino G. 2009. p73, miR106b, miR34a, and Itch in chronic lymphocytic leukemia. Blood 113:6498-6499; author reply 6499-6500.
114. Romano RA, Smalley K, Magraw C, Serna VA, Kurita T, Raghavan S, Sinha S. 2012. DeltaNp63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation. Development 139:772-782.
115. Rosenbluth JM, Mays DJ, Pino MF, Tang LJ, Pietenpol JA. 2008. A gene signature-based approach identifies mTOR as a regulator of p73. Mol Cell Biol 28:5951-5964.
116. Rossi M, Aqeilan RI, Neale M, Candi E, Salomoni P, Knight RA, Croce CM, Melino G. 2006. The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc Natl Acad Sci USA 103:12753-12758.
117. Rossi M, De Laurenzi V, Munarriz E, Green DR, Liu YC, Vousden KH, Cesareni G, Melino G. 2005. The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J 24:836-848.
118. Rossi M, Inoue S, Walewska R, Knight RA, Dyer MJ, Cohen GM, Melino G. 2009. Caspase cleavage of Itch in chronic lymphocytic leukemia cells. Biochem Biophys Res Commun 379:659-664.
119. Rufini A, Agostini M, Grespi F, Tomasini R, Sayan BS, Niklison-Chirou MV, Conforti F, Velletri T, Mastino A, Mak TW, Melino G, Knight RA. 2011. p73 in cancer. Genes Cancer 2:491-502.
120. Rufini A, Niklison-Chirou MV, Inoue S, Tomasini R, Harris IS, Marino A, Federici M, Dinsdale D, Knight RA, Melino G, Mak TW. 2012. TAp73 depletion accelerates aging through metabolic dysregulation. Genes Dev 26:2009-2014.
121. Salomoni P, Dvorkina M, Michod D. 2012. Role of the promyelocytic leukaemia protein in cell death regulation. Cell Death Dis 3:e247.
122. Sampath D, Calin GA, Puduvalli VK, Gopisetty G, Taccioli C, Liu CG, Ewald B, Liu C, Keating MJ, Plunkett W. 2009. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 113:3744-3753.
123. Sanchez-Prieto R, Sanchez-Arevalo VJ, Servitja JM, Gutkind JS. 2002. Regulation of p73 by c-Abl through the p38 MAP kinase pathway. Oncogene 21:974-979.
124. Sayan BS, Yang AL, Conforti F, Tucci P, Piro MC, Browne GJ, Agostini M, Bernardini S, Knight RA, Mak TW, Melino G. 2010. Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2. Proc Natl Acad Sci USA 107:12877-12882.
125. Scheel AH, Beyer U, Agami R, Dobbelstein M. 2009. Immunofluorescence-based screening identifies germ cell associated microRNA 302 as an antagonist to p63 expression. Cell Cycle 8:1426-1432.
126. Sen T, Chang X, Sidransky D, Chatterjee A. 2010. Regulation of DeltaNp63alpha by NFkappaBeta. Cell Cycle 9:4841-4847.
127. Sen T, Sen N, Huang Y, Sinha D, Luo ZG, Ratovitski EA, Sidransky D. 2011. Tumor protein p63/nuclear factor kappaB feedback loop in regulation of cell death. J Biol Chem 286:43204-43213.
128. Senoo M, Pinto F, Crum CP, McKeon F. 2007. p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell 129:523-536.
129. Stiewe T, Theseling CC, Putzer BM. 2002. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem 277:14177-14185.
130. Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, Mantovani F, Damalas A, Citro G, Sacchi A, Del Sal G, Levrero M, et al. 2005. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. Mol Cell 18:447-459.
131. Straub WE, Weber TA, Schafer B, Candi E, Durst F, Ou HD, Rajalingam K, Melino G, Dotsch V. 2010. The C-terminus of p63 contains multiple regulatory elements with different functions. Cell Death Dis 1:e5.
132. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, Leung ML, El-Naggar A, Creighton CJ, Suraokar MB, Wistuba I, Flores ER. 2010. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 467:986-990.
133. Su X, Gi YJ, Chakravarti D, Chan IL, Zhang A, Xia X, Tsai KY, Flores ER. 2012. TAp63 is a master transcriptional regulator of lipid and glucose metabolism. Cell Metab 16:511-525.
134. Suh EK, Yang A, Kettenbach A, Bamberger C, Michaelis AH, Zhu Z, Elvin JA, Bronson RT, Crum CP, McKeon F. 2006. p63 protects the female germ line during meiotic arrest. Nature 444:624-628.
135. Talos F, Abraham A, Vaseva AV, Holembowski L, Tsirka SE, Scheel A, Bode D, Dobbelstein M, Bruck W, Moll UM. 2010. p73 is an essential regulator of neural stem cell maintenance in embryonal and adult CNS neurogenesis. Cell Death Differ 17:1816-1829.
136. Thurfjell N, Coates PJ, Vojtesek B, Benham-Motlagh P, Eisold M, Nylander K. 2005. Endogenous p63 acts as a survival factor for tumour cells of SCCHN origin. Int J Mol Med 16:1065-1070.
137. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC, Khan F, Itie-Youten A, Wakeham A, Tsao MS, Iovanna JL, Squire J, et al. 2008. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 22:2677-2691.
138. Tran MN, Choi W, Wszolek MF, Navai N, Lee IL, Nitti G, Wen S, Flores ER, Siefker-Radtke A, Czerniak B, Dinney C, Barton M, et al. 2013. The p63 protein isoform DeltaNp63alpha inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. J Biol Chem 288:3275-3288.
139. Tsai KK, Yuan ZM. 2003. c-Abl stabilizes p73 by a phosphorylation-augmented interaction. Cancer Res 63:3418-3424.
140. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH, Muller PA, Dotsch V, Kehrloesser S, Sayan BS, Giaccone G, Lowe SW, et al. 2012. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci USA 109:15312-15317.
141. Vanbokhoven H, Melino G, Candi E, Declercq W. 2011. p63, a story of mice and men. J Invest Dermatol 131:1196-1207.
142. Vanlangenakker N, Vanden Berghe T, Vandenabeele P. 2012. Many stimuli pull the necrotic trigger, an overview. Cell Death Differ 19:75-86.
143. Vigano MA, Lamartine J, Testoni B, Merico D, Alotto D, Castagnoli C, Robert A, Candi E, Melino G, Gidrol X, Mantovani R. 2006. New p63 targets in keratinocytes identified by a genome-wide approach. EMBO J 25:5105-5116.
144. Viticchie G, Lena AM, Cianfarani F, Odorisio T, Annicchiarico-Petruzzelli M, Melino G, Candi E. 2012. MicroRNA-203 contributes to skin re-epithelialization. Cell Death Dis 3:e435.
145. Vousden KH, Ryan KM. 2009. p53 and metabolism. Nat Rev Cancer 9:691-700.
146. White E. 2012. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 12:401-410.
147. Wilhelm MT, Rufini A, Wetzel MK, Tsuchihara K, Inoue S, Tomasini R, Itie-Youten A, Wakeham A, Arsenian-Henriksson M, Melino G, Kaplan DR, Miller FD, et al. 2010. Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev 24:549-560.
148. Wu J, Bergholz J, Lu J, Sonenshein GE, Xiao ZX. 2010. TAp63 is a transcriptional target of NF-kappaB. J Cell Biochem 109:702-710.
149. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F. 1998. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2:305-316.
150. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, McKeon F. 1999. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398:714-718.
151. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D. 2000. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404:99-103.
152. Yuan M, Luong P, Hudson C, Gudmundsdottir K, Basu S. 2010. c-Abl phosphorylation of DeltaNp63alpha is critical for cell viability. Cell Death Dis 1:e16.
153. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E, Moll UM. 2002. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 196:765-780.
154. Zangen R, Ratovitski E, Sidransky D. 2005. DeltaNp63alpha levels correlate with clinical tumor response to cisplatin. Cell Cycle 4:1313-1315.
155. Zdzalik M, Pustelny K, Kedracka-Krok S, Huben K, Pecak A, Wladyka B, Jankowski S, Dubin A, Potempa J, Dubin G. 2010. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73. Cell Cycle 9:4584-4591.
156. Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X, Kaelin WG Jr., Oren M, Chen J, Lu H. 1999. MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 19:3257-3266.